| Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary … D Sibbing, D Aradi, D Alexopoulos, J Ten Berg, DL Bhatt, L Bonello, ... JACC: Cardiovascular Interventions 12 (16), 1521-1537, 2019 | 526 | 2019 |
| International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies DJ Angiolillo, F Rollini, RF Storey, DL Bhatt, S James, DJ Schneider, ... Circulation 136 (20), 1955-1975, 2017 | 439 | 2017 |
| Novel antiplatelet agents in acute coronary syndrome F Franchi, DJ Angiolillo Nature Reviews Cardiology 12 (1), 30-47, 2015 | 406 | 2015 |
| Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention D Capodanno, R Mehran, M Valgimigli, U Baber, S Windecker, P Vranckx, ... Nature Reviews Cardiology 15 (8), 480-496, 2018 | 222 | 2018 |
| Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease DJ Angiolillo, JA Jakubowski, JL Ferreiro, A Tello-Montoliu, F Rollini, ... Journal of the American College of Cardiology 64 (10), 1005-1014, 2014 | 215 | 2014 |
| Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis M Galli, S Benenati, D Capodanno, F Franchi, F Rollini, D D'Amario, ... The Lancet 397 (10283), 1470-1483, 2021 | 212 | 2021 |
| Switching P2Y12-receptor inhibitors in patients with coronary artery disease F Rollini, F Franchi, DJ Angiolillo Nature Reviews Cardiology 13 (1), 11-27, 2016 | 183 | 2016 |
| Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention … F Franchi, F Rollini, A Rivas, M Wali, M Briceno, M Agarwal, Z Shaikh, ... Circulation 139 (14), 1661-1670, 2019 | 153 | 2019 |
| Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials M Galli, S Benenati, F Franchi, F Rollini, D Capodanno, G Biondi-Zoccai, ... European heart journal 43 (10), 959-967, 2022 | 149 | 2022 |
| Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial RF Storey, DJ Angiolillo, MP Bonaca, MR Thomas, HM Judge, F Rollini, ... Journal of the American College of Cardiology 67 (10), 1145-1154, 2016 | 147 | 2016 |
| Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study F Rollini, F Franchi, J Hu, M Kureti, N Aggarwal, A Durairaj, Y Park, ... Journal of the American College of Cardiology 67 (17), 1994-2004, 2016 | 144 | 2016 |
| Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy PE Empey, JM Stevenson, S Tuteja, KW Weitzel, DJ Angiolillo, ... Clinical Pharmacology & Therapeutics 104 (4), 664-674, 2018 | 133 | 2018 |
| Antithrombotic therapy for patients with STEMI undergoing primary PCI F Franchi, F Rollini, DJ Angiolillo Nature Reviews Cardiology 14 (6), 361-379, 2017 | 113 | 2017 |
| Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in … F Franchi, F Rollini, N Aggarwal, J Hu, M Kureti, A Durairaj, VE Duarte, ... Circulation 134 (11), 780-792, 2016 | 94 | 2016 |
| Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium D Capodanno, R Mehran, MW Krucoff, U Baber, DL Bhatt, P Capranzano, ... Circulation 147 (25), 1933-1944, 2023 | 90 | 2023 |
| Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention … F Franchi, F Rollini, JR Cho, M Bhatti, C DeGroat, E Ferrante, EC Dunn, ... Cardiovascular Interventions 8 (11), 1457-1467, 2015 | 86 | 2015 |
| Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy JY Moon, F Franchi, F Rollini, DJ Angiolillo Progress in cardiovascular diseases 60 (4-5), 478-490, 2018 | 80 | 2018 |
| Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis … L Ortega-Paz, M Galli, D Capodanno, F Franchi, F Rollini, B Bikdeli, ... European Heart Journal-Cardiovascular Pharmacotherapy 8 (7), 677-686, 2022 | 75 | 2022 |
| Institutional profile: University of Florida health personalized medicine program LH Cavallari, KW Weitzel, AR Elsey, X Liu, SA Mosley, DM Smith, ... Pharmacogenomics 18 (5), 421-426, 2017 | 74 | 2017 |
| A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective … F Rollini, F Franchi, JR Cho, C DeGroat, M Bhatti, A Muniz-Lozano, ... European heart journal 37 (35), 2722-2730, 2016 | 71 | 2016 |
Dominick AngiolilloUniversity of FloridaEmail được xác minh tại jax.ufl.edu
